AZD8309

TargetMol
Product Code: TAR-T25131
Supplier: TargetMol
CodeSizePrice
TAR-T25131-1mg1mg£198.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25131-5mg5mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25131-10mg10mg£544.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25131-25mg25mg£830.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25131-50mg50mg£1,099.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25131-100mg100mg£1,460.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25131-500mg500mg£2,850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
AZD8309 is a CXCR2 antagonist that has orally active.
CAS:
333742-48-6
Formula:
C15H14F2N4O2S2
Molecular Weight:
384.42
Pathway:
GPCR/G Protein|Autophagy|Metabolism|Immunology/Inflammation
Purity:
0.98
SMILES:
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12
Target:
Glutathione Peroxidase|CXCR

References

1. Malla SR, K?rrman M?rdh C, G?nther A, Mahajan UM, Sendler M, D'Haese J, Weiss FU, Lerch MM, Hansen MB, Mayerle J. Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis. Pancreatology. 2016 Sep-Oct;16(5):761-9. doi: 10.1016/j.pan.2016.07.005. Epub 2016 Jul 14. PubMed PMID: 27450968. 2. Leaker BR, Barnes PJ, O'Connor B. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res. 2013 Dec 16;14:137. doi: 10.1186/1465-9921-14-137. PubMed PMID: 24341382; PubMed Central PMCID: PMC3867427. 3. Virtala R, Ekman AK, Jansson L, Westin U, Cardell LO. Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. Clin Exp Allergy. 2012 Apr;42(4):590-6. doi: 10.1111/j.1365-2222.2011.03921.x. Epub 2011 Dec 22. PubMed PMID: 22192144.